Discounted Cash Flow (DCF) Analysis Levered
BioNano Genomics, Inc. WT EXP 08212... (BNGOW)
$0.05
+0.01 (+19.90%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -0.33 | -0.06 | -0.14 | -0.30 | -0.47 | -0.63 | -0.84 | -1.12 | -1.49 | -1.99 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -20.28 | -29.59 | -38.46 | -72.23 | -125.28 | -131.18 | -175.26 | -234.17 | -312.87 | -418.02 |
Weighted Average Cost Of Capital
Share price | $ 0.05 |
---|---|
Beta | 0.000 |
Diluted Shares Outstanding | - |
Cost of Debt | |
Tax Rate | -1.44 |
After-tax Cost of Debt | 2.55% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 3.608 |
Total Debt | 11.67 |
Total Equity | - |
Total Capital | - |
Debt Weighting | - |
Equity Weighting | - |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
Capital Expenditure | -0.33 | -0.06 | -0.14 | -0.30 | -0.47 | -0.63 | -0.84 | -1.12 | -1.49 | -1.99 |
Free Cash Flow | -20.28 | -29.59 | -38.46 | -72.23 | -125.28 | -131.18 | -175.26 | -234.17 | -312.87 | -418.02 |
WACC | ||||||||||
PV LFCF | - | - | - | - | - | |||||
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | - |
Free cash flow (t + 1) | -426.38 |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | 6.58 |
Equity Value | - |
Shares Outstanding | - |
Equity Value Per Share | - |